Encorafenib

Generic name: Pronounced as (en" koe raf' e nib)
Brand names
  • Braftovi®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 05/15/2020

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the body after other treatment(s). Encorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Encorafenib comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take encorafenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take encorafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

If you vomit after taking the medication, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease or temporarily or permanently stop your treatment depending on if you experience any side effects. Be sure to tell your doctor how you are feeling during your treatment with encorafenib.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking encorafenib,

  • tell your doctor and pharmacist if you are allergic to encorafenib, any other medications, or any of the ingredients in encorafenib capsules. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products} you are taking or plan to take. Be sure to mention any of the following: amiodarone (Nexterone, Pacerone), carbamazepine (Carbatrol, Teril, others), citalopram (Celexa), clarithromycin (Biaxin, in Prevpac), diltiazem (Cardizem, Cartia, Diltzac, others), disopyramide (Norpace), erythromycin (E.E.S, PCE, others), efavirenz (Sustiva, in Atripla), indinavir (Crixivan), itraconazole (Onmel, Sporanox), ketoconazole, modafinil (Provigil), nefazodone, nelfinavir (Viracept), nevirapine (Viramune), phenobarbital, phenytoin (Dilantin, Phenytek), procainamide, quinidine (in Nuedexta), rifampin (Rifadin, Rimactane, in Rifamate, in Rifater), ritonavir (Norvir, in Kaletra), sotalol (Betapace, Sotylize), and verapamil (Calan, Verelan, in Tarka). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with encorafenib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

  • tell your doctor what herbal products you are taking, especially St John's wort.

  • tell your doctor if you have or have ever had a QT interval prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death), low levels of potassium or magnesium in your blood, heart failure, or liver disease.

  • tell your doctor if you are pregnant or plan to become pregnant. You will have to take a pregnancy test before starting treatment. You should use a nonhormonal birth control to prevent pregnancy during your treatment with encorafenib and for 2 weeks after your final dose. Encorafenib may decrease the effectiveness of oral contraceptives (birth control pills), so it is especially important to use a nonhormonal form of birth control. Talk to your doctor about methods of birth control that will work for you. If you become pregnant while taking encorafenib, call your doctor immediately. Encorafenib may harm the fetus.

  • tell your doctor if you are breastfeeding. Do not breastfeed while you are taking encorafenib and for 2 weeks after your final dose.

  • you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of taking encorafenib.

Do not eat grapefruit or drink grapefruit juice while taking this medication.

Take the missed dose as soon as you remember it. However, if it is within 12 hours of the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Encorafenib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • fatigue

    • fever

    • nausea

    • stomach pain

    • constipation

    • headache

    • dizziness

    • redness, swelling, numbness and skin peeling of hands and soles of feet

    • skin thickening

    • rash

    • dry skin

    • hair loss

    • joint or muscle pain

    • change in taste

    • back pain

    • acne

    • nose bleeding

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

    • dizziness, fainting, or feeling faint

    • vision changes

    • skin changes such as new wart, a sore or reddish bump that does not heal, a change in the size or color of a mole

    • unusual bleeding or bruising

    • black, tarry, or bloody stools

    • coughing up blood

  • Encorafenib may cause an increased risk of developing cancer, including skin cancer. Your doctor will check your skin before treatment, every 2 months during treatment, and for up to 6 months after your final dose of encorafenib for signs of skin cancer. Talk to your doctor about the risks of taking this medication.

  • Encorafenib may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom). Do not remove the desiccant (drying agent) from the bottle.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor, eye doctor, and the laboratory. Your doctor will order a lab test before you begin your treatment to see whether your cancer can be treated with encorafenib. Your doctor may order certain lab tests, including eye exams, to check your body's response to encorafenib.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Encorafenib.
Delavirdine Delavirdine The metabolism of Encorafenib can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Encorafenib can be decreased when combined with Nevirapine.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Encorafenib.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Anagrelide.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Encorafenib.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Encorafenib.
Penbutolol Penbutolol The metabolism of Encorafenib can be decreased when combined with Acebutolol.
Ranitidine Ranitidine The metabolism of Encorafenib can be decreased when combined with Ranitidine.
Tacrolimus Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Encorafenib.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Encorafenib.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Encorafenib.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Encorafenib.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Encorafenib.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Encorafenib.
Meperidine Injection Meperidine Injection The metabolism of Encorafenib can be decreased when combined with Meperidine.
Metoclopramide Injection Metoclopramide Injection The metabolism of Encorafenib can be decreased when combined with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Encorafenib.
Altretamine Altretamine The metabolism of Encorafenib can be decreased when combined with Amphetamine.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Encorafenib.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Encorafenib.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Encorafenib.
Olanzapine Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Encorafenib.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Dofetilide.
Entacapone Entacapone The metabolism of Encorafenib can be decreased when combined with Entacapone.
Hydroxychloroquine Hydroxychloroquine The metabolism of Encorafenib can be decreased when combined with Hydroxychloroquine.
Anakinra Anakinra The metabolism of Encorafenib can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Encorafenib.
Trimipramine Trimipramine The metabolism of Encorafenib can be decreased when combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Encorafenib can be increased when combined with Etanercept.
Escitalopram Escitalopram The serum concentration of Encorafenib can be increased when it is combined with Escitalopram.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Encorafenib.
Adalimumab Injection Adalimumab Injection The metabolism of Encorafenib can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Encorafenib.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Encorafenib.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Encorafenib.
Almotriptan Almotriptan The metabolism of Encorafenib can be decreased when combined with Almotriptan.
Eletriptan Eletriptan The metabolism of Encorafenib can be decreased when combined with Eletriptan.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Encorafenib.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Encorafenib.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Encorafenib.
Tegaserod Tegaserod The metabolism of Encorafenib can be decreased when combined with Tegaserod.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Encorafenib.
Progesterone Progesterone The metabolism of Encorafenib can be decreased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Encorafenib.
Darbepoetin Alfa Injection Darbepoetin Alfa Injection The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Encorafenib.
Infliximab Injection Infliximab Injection The metabolism of Encorafenib can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Encorafenib.
Duloxetine Duloxetine The metabolism of Encorafenib can be decreased when combined with Duloxetine.
Trospium Trospium The metabolism of Encorafenib can be decreased when combined with Trospium.
Cinacalcet Cinacalcet The metabolism of Encorafenib can be decreased when combined with Cinacalcet.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Encorafenib.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Encorafenib.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Encorafenib.
Dextroamphetamine Dextroamphetamine The metabolism of Encorafenib can be decreased when combined with Amphetamine.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The metabolism of Encorafenib can be decreased when combined with Peginterferon alfa-2b.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Encorafenib.
Darifenacin Darifenacin The metabolism of Darifenacin can be decreased when combined with Encorafenib.
Pregabalin Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Encorafenib.
Tipranavir Tipranavir The metabolism of Tipranavir can be decreased when combined with Encorafenib.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Encorafenib.
Ranolazine Ranolazine The serum concentration of Encorafenib can be increased when it is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Encorafenib can be increased when combined with Abatacept.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Encorafenib.
Gefitinib Gefitinib The metabolism of Encorafenib can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Encorafenib.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Encorafenib.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Encorafenib.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Encorafenib.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Encorafenib.
Primaquine Primaquine The metabolism of Encorafenib can be decreased when combined with Primaquine.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Encorafenib.
Lisdexamfetamine Lisdexamfetamine The metabolism of Encorafenib can be decreased when combined with Lisdexamfetamine.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Encorafenib.
Sorafenib Sorafenib The metabolism of Encorafenib can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Encorafenib.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Encorafenib.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Encorafenib.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Encorafenib.
Mexiletine Mexiletine The metabolism of Encorafenib can be decreased when combined with Mexiletine.
Temsirolimus Temsirolimus The metabolism of Encorafenib can be decreased when combined with Temsirolimus.
Nilotinib Nilotinib The metabolism of Encorafenib can be decreased when combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Toremifene.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The metabolism of Encorafenib can be decreased when combined with Desvenlafaxine.
Cevimeline Cevimeline The metabolism of Encorafenib can be decreased when combined with Cevimeline.
Nebivolol Nebivolol The metabolism of Encorafenib can be decreased when combined with Nebivolol.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Encorafenib.
Certolizumab Injection Certolizumab Injection The metabolism of Encorafenib can be increased when combined with Certolizumab pegol.
Fesoterodine Fesoterodine The metabolism of Encorafenib can be decreased when combined with Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Encorafenib.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Encorafenib.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Encorafenib.
Everolimus Everolimus The metabolism of Encorafenib can be decreased when combined with Everolimus.
Dronedarone Dronedarone The metabolism of Encorafenib can be decreased when combined with Dronedarone.
Palonosetron Injection Palonosetron Injection The metabolism of Encorafenib can be decreased when combined with Palonosetron.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Encorafenib.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Romidepsin.
Tapentadol Tapentadol The metabolism of Encorafenib can be decreased when combined with Tapentadol.
Golimumab Injection Golimumab Injection The metabolism of Encorafenib can be increased when combined with Golimumab.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Encorafenib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Asenapine.
Oxymorphone Oxymorphone The metabolism of Encorafenib can be decreased when combined with Oxymorphone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Encorafenib can be increased when combined with Tocilizumab.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Encorafenib.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Encorafenib.
Acetaminophen Injection Acetaminophen Injection The metabolism of Encorafenib can be decreased when combined with Acetaminophen.
Vilazodone Vilazodone The metabolism of Encorafenib can be decreased when combined with Vilazodone.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Encorafenib.
Rilpivirine Rilpivirine The metabolism of Encorafenib can be decreased when combined with Rilpivirine.
Abiraterone Abiraterone The metabolism of Encorafenib can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Encorafenib.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Vandetanib.
Clobazam Clobazam The metabolism of Encorafenib can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Encorafenib.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Encorafenib.
Mirabegron Mirabegron The metabolism of Encorafenib can be decreased when combined with Mirabegron.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Encorafenib.
Alogliptin Alogliptin The metabolism of Encorafenib can be decreased when combined with Alogliptin.
Ponatinib Ponatinib The metabolism of Encorafenib can be decreased when combined with Ponatinib.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Encorafenib.
Ospemifene Ospemifene The metabolism of Encorafenib can be decreased when combined with Ospemifene.
Levomilnacipran Levomilnacipran The metabolism of Encorafenib can be decreased when combined with Levomilnacipran.
Vortioxetine Vortioxetine The metabolism of Encorafenib can be decreased when combined with Vortioxetine.
Ibrutinib Ibrutinib The metabolism of Encorafenib can be decreased when combined with Ibrutinib.
Dapagliflozin Dapagliflozin The metabolism of Encorafenib can be decreased when combined with Dapagliflozin.
Apremilast Apremilast The metabolism of Encorafenib can be increased when combined with Apremilast.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Encorafenib.
Siltuximab Injection Siltuximab Injection The metabolism of Encorafenib can be increased when combined with Siltuximab.
Oritavancin Injection Oritavancin Injection The metabolism of Encorafenib can be decreased when combined with Oritavancin.
Methamphetamine Methamphetamine The metabolism of Encorafenib can be decreased when combined with Metamfetamine.
Secukinumab Injection Secukinumab Injection The metabolism of Encorafenib can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of QTc prolongation can be increased when Risperidone is combined with Encorafenib.
Lenvatinib Lenvatinib The metabolism of Encorafenib can be decreased when combined with Lenvatinib.
Naloxegol Naloxegol The metabolism of Encorafenib can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Encorafenib can be decreased when combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The serum concentration of Encorafenib can be increased when it is combined with Haloperidol.
Ivabradine Ivabradine Ivabradine may increase the QTc-prolonging activities of Encorafenib.
Rolapitant Rolapitant The metabolism of Encorafenib can be decreased when combined with Rolapitant.
Brexpiprazole Brexpiprazole The metabolism of Encorafenib can be decreased when combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Encorafenib.
Cariprazine Cariprazine The metabolism of Encorafenib can be decreased when combined with Cariprazine.
Trabectedin Injection Trabectedin Injection The metabolism of Encorafenib can be decreased when combined with Trabectedin.
Cobicistat Cobicistat The metabolism of Encorafenib can be decreased when combined with Cobicistat.
Diphenhydramine Injection Diphenhydramine Injection The metabolism of Encorafenib can be decreased when combined with Diphenhydramine.
Rucaparib Rucaparib The metabolism of Encorafenib can be decreased when combined with Rucaparib.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) The metabolism of Encorafenib can be decreased when combined with Doxepin.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Deutetrabenazine.
Valbenazine Valbenazine The metabolism of Valbenazine can be decreased when combined with Encorafenib.
Safinamide Safinamide The metabolism of Encorafenib can be decreased when combined with Safinamide.
Midostaurin Midostaurin The metabolism of Encorafenib can be decreased when combined with Midostaurin.
Enasidenib Enasidenib The metabolism of Encorafenib can be decreased when combined with Enasidenib.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Encorafenib.
Letermovir Letermovir The metabolism of Letermovir can be decreased when combined with Encorafenib.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Encorafenib.
Buprenorphine Injection Buprenorphine Injection The metabolism of Encorafenib can be decreased when combined with Buprenorphine.
Lofexidine Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Encorafenib.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Ivosidenib.
Elagolix Elagolix The metabolism of Elagolix can be decreased when combined with Encorafenib.
Tafenoquine Tafenoquine The metabolism of Encorafenib can be decreased when combined with Tafenoquine.
Cannabidiol Cannabidiol The metabolism of Encorafenib can be decreased when combined with Cannabidiol.
Dacomitinib Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Encorafenib.
Stiripentol Stiripentol The metabolism of Encorafenib can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Glasdegib.
Methoxy Polyethylene Glycol-Epoetin Beta Injection Methoxy Polyethylene Glycol-Epoetin Beta Injection The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Encorafenib.
Rifamycin Rifamycin The metabolism of Encorafenib can be decreased when combined with Rifamycin.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Encorafenib can be increased when combined with Emapalumab.
Triclabendazole Triclabendazole The metabolism of Encorafenib can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Entrectinib.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Encorafenib.
Pitolisant Pitolisant The serum concentration of Encorafenib can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The metabolism of Encorafenib can be decreased when combined with Fedratinib.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Encorafenib.
Phenytoin Injection Phenytoin Injection The metabolism of Encorafenib can be decreased when combined with Phenytoin.
Cenobamate Cenobamate The serum concentration of Encorafenib can be decreased when it is combined with Cenobamate.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Encorafenib.
Fenfluramine Fenfluramine The metabolism of Encorafenib can be decreased when combined with Fenfluramine.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Encorafenib.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encorafenib.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Encorafenib can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Encorafenib.
Theophylline Theophylline The metabolism of Encorafenib can be decreased when combined with Theophylline.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Encorafenib.
Hydroxyurea Hydroxyurea The metabolism of Encorafenib can be decreased when combined with Hydroxyurea.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Encorafenib.
Chlorpromazine Chlorpromazine The metabolism of Encorafenib can be decreased when combined with Chlorpromazine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Encorafenib.
Codeine Codeine The metabolism of Encorafenib can be decreased when combined with Codeine.
Tranylcypromine Tranylcypromine The metabolism of Encorafenib can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine The metabolism of Encorafenib can be decreased when combined with Phenelzine.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Encorafenib.
Thioridazine Thioridazine The metabolism of Encorafenib can be decreased when combined with Thioridazine.
Oxycodone Oxycodone The metabolism of Encorafenib can be decreased when combined with Oxycodone.
Methadone Methadone The metabolism of Encorafenib can be decreased when combined with Methadone.
Oxybutynin Oxybutynin The metabolism of Encorafenib can be decreased when combined with Oxybutynin.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Encorafenib.
Maprotiline Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Encorafenib.
Orphenadrine Orphenadrine The metabolism of Encorafenib can be decreased when combined with Orphenadrine.
Perphenazine Perphenazine The metabolism of Encorafenib can be decreased when combined with Perphenazine.
Fluphenazine Fluphenazine The metabolism of Encorafenib can be decreased when combined with Fluphenazine.
Amoxapine Amoxapine The metabolism of Encorafenib can be decreased when combined with Amoxapine.
Doxorubicin Doxorubicin The metabolism of Encorafenib can be decreased when combined with Doxorubicin.
Clonidine Clonidine The metabolism of Encorafenib can be decreased when combined with Clonidine.
Cimetidine Cimetidine The metabolism of Encorafenib can be decreased when combined with Cimetidine.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Encorafenib.
Promethazine Promethazine The metabolism of Encorafenib can be decreased when combined with Promethazine.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Encorafenib.
Chloroquine Chloroquine The metabolism of Encorafenib can be decreased when combined with Chloroquine.
Quinine Quinine The metabolism of Encorafenib can be decreased when combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Encorafenib.
Desipramine Desipramine The metabolism of Desipramine can be decreased when combined with Encorafenib.
Amitriptyline Amitriptyline The metabolism of Encorafenib can be decreased when combined with Amitriptyline.
Imipramine Imipramine The metabolism of Imipramine can be decreased when combined with Encorafenib.
Quinidine Quinidine The metabolism of Encorafenib can be decreased when combined with Quinidine.
Procainamide Procainamide The metabolism of Procainamide can be decreased when combined with Encorafenib.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Valproic acid.
Tamoxifen Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Encorafenib.
Methimazole Methimazole The metabolism of Encorafenib can be decreased when combined with Methimazole.
Dextromethorphan Dextromethorphan The metabolism of Encorafenib can be decreased when combined with Dextromethorphan.
Niacin Niacin The metabolism of Encorafenib can be decreased when combined with Niacin.
Doxylamine Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Encorafenib.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Encorafenib.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Encorafenib.
Chlorpheniramine Chlorpheniramine The metabolism of Encorafenib can be decreased when combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Encorafenib.
Meclizine Meclizine The metabolism of Encorafenib can be decreased when combined with Meclizine.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Encorafenib.
Chlorzoxazone Chlorzoxazone The metabolism of Encorafenib can be decreased when combined with Chlorzoxazone.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Encorafenib.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Propranolol is combined with Encorafenib.
Nortriptyline Nortriptyline The metabolism of Encorafenib can be decreased when combined with Nortriptyline.
Nadolol Nadolol The metabolism of Encorafenib can be decreased when combined with Nadolol.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encorafenib.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Encorafenib.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Encorafenib.
Ketoconazole Ketoconazole The metabolism of Encorafenib can be decreased when combined with Ketoconazole.
Vinblastine Vinblastine The metabolism of Encorafenib can be decreased when combined with Vinblastine.
Metoprolol Metoprolol The metabolism of Encorafenib can be decreased when combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Encorafenib.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Encorafenib.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Encorafenib.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Encorafenib.
Nifedipine Nifedipine The metabolism of Encorafenib can be decreased when combined with Nifedipine.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Encorafenib.
Verapamil Verapamil The metabolism of Encorafenib can be decreased when combined with Verapamil.
Atenolol Atenolol The metabolism of Encorafenib can be decreased when combined with Atenolol.
Pindolol Pindolol The metabolism of Encorafenib can be decreased when combined with Pindolol.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Encorafenib.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Encorafenib.
Labetalol Labetalol The metabolism of Encorafenib can be decreased when combined with Labetalol.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Encorafenib.
Pimozide Pimozide The metabolism of Encorafenib can be decreased when combined with Pimozide.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Encorafenib.
Buspirone Buspirone The metabolism of Encorafenib can be decreased when combined with Buspirone.
Lovastatin Lovastatin The metabolism of Encorafenib can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Encorafenib.
Fluoxetine Fluoxetine The serum concentration of Encorafenib can be increased when it is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Encorafenib.
Clozapine Clozapine The metabolism of Encorafenib can be decreased when combined with Clozapine.
Idarubicin Idarubicin The metabolism of Encorafenib can be decreased when combined with Idarubicin.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Encorafenib.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Encorafenib.
Felodipine Felodipine The metabolism of Encorafenib can be decreased when combined with Felodipine.
Simvastatin Simvastatin The metabolism of Encorafenib can be decreased when combined with Simvastatin.
Epoetin Alfa, Injection Epoetin Alfa, Injection The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Encorafenib.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Encorafenib.
Sotalol Sotalol The metabolism of Sotalol can be decreased when combined with Encorafenib.
Zolpidem Zolpidem The metabolism of Encorafenib can be decreased when combined with Zolpidem.
Doxazosin Doxazosin The metabolism of Encorafenib can be decreased when combined with Doxazosin.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Encorafenib.
Omeprazole Omeprazole The metabolism of Encorafenib can be decreased when combined with Omeprazole.
Cisapride Cisapride The metabolism of Encorafenib can be decreased when combined with Cisapride.
Fluvastatin Fluvastatin The metabolism of Encorafenib can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The metabolism of Encorafenib can be decreased when combined with Venlafaxine.
Fluvoxamine Fluvoxamine The metabolism of Encorafenib can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The metabolism of Encorafenib can be decreased when combined with Nefazodone.
Lamotrigine Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Encorafenib.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Encorafenib.
Tramadol Tramadol The metabolism of Encorafenib can be decreased when combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The metabolism of Encorafenib can be decreased when combined with Vinorelbine.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Encorafenib.
Lansoprazole Lansoprazole The metabolism of Encorafenib can be decreased when combined with Lansoprazole.
Nicardipine Nicardipine The metabolism of Encorafenib can be decreased when combined with Nicardipine.
Bupropion Bupropion The metabolism of Encorafenib can be decreased when combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Encorafenib can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Encorafenib.
Ritonavir Ritonavir The serum concentration of Encorafenib can be increased when it is combined with Ritonavir.
Clomipramine Clomipramine The metabolism of Encorafenib can be decreased when combined with Clomipramine.
Mirtazapine Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Encorafenib.
Donepezil Donepezil The metabolism of Encorafenib can be decreased when combined with Donepezil.
Nelfinavir Nelfinavir The metabolism of Encorafenib can be decreased when combined with Nelfinavir.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Encorafenib.
Carvedilol Carvedilol The metabolism of Encorafenib can be decreased when combined with Carvedilol.
Selegiline Selegiline The metabolism of Encorafenib can be decreased when combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Encorafenib can be decreased when combined with Bicalutamide.
Sertraline Sertraline The metabolism of Encorafenib can be decreased when combined with Sertraline.
Propafenone Propafenone The metabolism of Encorafenib can be decreased when combined with Propafenone.
Tamsulosin Tamsulosin The metabolism of Encorafenib can be decreased when combined with Tamsulosin.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Encorafenib.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Encorafenib.
Paroxetine Paroxetine The metabolism of Encorafenib can be decreased when combined with Paroxetine.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Encorafenib.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Encorafenib.
Sildenafil Sildenafil The metabolism of Encorafenib can be decreased when combined with Sildenafil.
Celecoxib Celecoxib The metabolism of Encorafenib can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Encorafenib can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Encorafenib.
Nateglinide Nateglinide The metabolism of Encorafenib can be decreased when combined with Nateglinide.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Encorafenib.
Rabeprazole Rabeprazole The metabolism of Encorafenib can be decreased when combined with Rabeprazole.
Terbinafine Terbinafine The metabolism of Encorafenib can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists